| Line | All comers | FRα | Risk group |
|---|
| Early / localised | · | · | 1 |
| Advanced, first line | 1 | · | · |
| Third line and beyond | · | 1 | · |
| Other settings | 1 | · | · |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| Risk group | After allogeneic HSCT, high risk | Weekly plasma EBV DNA monitoring with pre-emptive rituximab when load rises; reduction of immunosuppression where possible. | | ECIL-6 guidelines (Haematologica 2016) | 92 |
Third line and beyond
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| FRα | EBV-positive, relapsed or refractory | EBV-specific T cells: tabelecleucel (EMA approval 2022; under FDA review) or institutional virus-specific T-cell programmes; clinical trials. | | EMA: Ebvallo (tabelecleucel) EPAR | 54 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | CD20-positive PTLD not responding to reduced immunosuppression | Rituximab weekly for four doses; patients in complete remission continue rituximab consolidation alone, others proceed to R-CHOP (PTLD-1 risk-stratified sequential treatment). | | NCCN · Category 2A | 84 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.